Maxim Group Sees 133% Upside in AIM ImmunoTech Inc. (AIM)

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) is among the best fundamentally strong penny stocks to buy right now. Jason McCarthy, an analyst at Maxim Group, initiated coverage on AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) with a ‘Buy’ rating and $6.00 price target. This implies a potential upside of nearly 133%.

Earlier this month, AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) shared the positive progress from its Ampligen clinical program in pancreatic cancer at the 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care, hosted at Poland’s National Institute of Oncology.

The management outlined data from the company’s pancreatic cancer Early Access Program, along with recent developments in the Phase 2 DURIPANC pancreatic cancer clinical trial, which is currently being conducted at Erasmus University Medical Center, located in the Netherlands.

As stated by CEO Thomas K. Equels,

“Ampligen continues to demonstrate its potential for the treatment of late-stage metastatic and locally advanced pancreatic cancer. Our growing body of positive data continues to bolster our confidence. This lethal malignancy is a high unmet need.”

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM), headquartered in Ocala, Florida, is an immuno-pharma company that researches and develops solutions for various types of cancers, viral diseases, and immune deficiency disorders.

While we acknowledge the potential of AIM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.